Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Share-based Compensation (2016 - 2026)

Dexcom has reported Share-based Compensation over the past 17 years, most recently at $43.3 million for Q1 2026.

  • Quarterly Share-based Compensation rose 26.61% to $43.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $168.7 million through Mar 2026, up 1.87% year-over-year, with the annual reading at $159.6 million for FY2025, 6.34% down from the prior year.
  • Share-based Compensation was $43.3 million for Q1 2026 at Dexcom, up from $35.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $45.3 million in Q2 2025 and troughed at $29.1 million in Q1 2022.
  • The 5-year median for Share-based Compensation is $39.0 million (2023), against an average of $38.3 million.
  • Year-over-year, Share-based Compensation rose 29.28% in 2022 and then decreased 19.17% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $34.0 million in 2022, then increased by 8.53% to $36.9 million in 2023, then grew by 17.34% to $43.3 million in 2024, then fell by 19.17% to $35.0 million in 2025, then increased by 23.71% to $43.3 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Share-based Compensation are $43.3 million (Q1 2026), $35.0 million (Q4 2025), and $45.1 million (Q3 2025).